Do you want to read an article? Please log in or register.
Baseline NT-proBNP Non-Response Score and Health Status Measures in Assessing Treatment Responses in Heart Failure with Reduced Ejection Fraction
Heart Failure
Related content
Heart Failure
Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry
Eur J Heart Fail
Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C
doi: 10.1002/ejhf.3565
Heart Failure
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
JACC Heart Fail
Lu H, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Voors AA, Senni M, Zannad F, Pitt B, Shah SJ, Lam CSP, Scheerer MF, Scalise A, Mueller K, Berger M, Goea L, McMurray JJV, Solomon SD
doi: 10.1016/j.jchf.2025.102590
Heart Failure
Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF
Eur J Heart Fail
Malgie J, Wilde MI, Koudstaal S, Denham R, da Fonseca CA, Swart HP, van Ofwegen CEE, Yilmaz A, Pisters R, Linssen GCM, Faber N, van Heerebeek L, van de Swaluw JEC, de Boer RA, Brunner-La Rocca HP, Brugts JJ
doi: 10.1002/ejhf.70006
COMMENTED
Heart Failure
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet Diabetes Endocrinol
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators
doi: 10.1016/S2213-8587(24)00304-8
Heart Failure
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction
JACC Heart Fail
Siqueira SRO, Pabon MA, Vaduganathan M, Claggett BL, Lam CSP, Kosiborod MN, de Boer RA, Shah SJ, Fang JC, Desai AS, Jhund PS, Inzucchi SE, Martinez F, Hernandez AF, Petersson M, McMurray JJV, Solomon SD, Vardeny O
doi: 10.1016/j.jchf.2025.102585
Heart Failure
Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document
Eur J Heart Fail
Bozkurt B, Mullens W, Leclercq C, Russo AM, Savarese G, Böhm M, Hill L, Kinugawa K, Sato N, Abraham WT, Bayes-Genis A, Mebazaa A, Rosano GMC, Zieroth S, Linde C, Butler J
doi: 10.1002/ejhf.3641
Heart Failure
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF
ESC Heart Fail
Ambrosy AP, Sauer AJ, Patel S, Windsor SL, Borlaug BA, Husain M, Inzucchi SE, Kitzman DW, McGuire DK, Shah SJ, Sharma K, Umpierrez G, Kosiborod MN
doi: 10.1002/ehf2.15184
Heart Failure
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial
J Am Heart Assoc
Nouhravesh N, Cyr D, Hernandez AF, Morrow DA, Velazquez EJ, Ward J, Sarwat S, Sharma K, Williamson K, Starling RC, Lepage S, Zieroth S, Solomon SD, Mentz RJ
doi: 10.1161/JAHA.124.037899
Heart Failure
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight
Eur J Heart Fail
Butt JH, Solomon SD, Vaduganathan M, van Veldhuisen DJ, Køber L, Pitt B, Zannad F, Jhund PS, McMurray JJV
doi: 10.1002/ejhf.3665